What are the criteria for staging acute kidney injury (AKI) and the recommended management for each stage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

AKI Staging Criteria

Use the KDIGO criteria to diagnose and stage acute kidney injury based on serum creatinine changes and/or urine output, with AKI defined as any increase in SCr ≥0.3 mg/dL within 48 hours OR increase to ≥1.5 times baseline within 7 days OR urine output <0.5 mL/kg/h for 6 hours. 1

Diagnostic Criteria for AKI

AKI is diagnosed when any one of the following occurs:

  • Serum creatinine increase ≥0.3 mg/dL (26.5 μmol/L) within 48 hours
  • Serum creatinine increase to ≥1.5 times baseline (known or presumed to have occurred within prior 7 days)
  • Urine output <0.5 mL/kg/h for 6 hours 1

Baseline Creatinine Definition

Use a serum creatinine value from the previous 3 months when available; if multiple values exist, use the one closest to admission. If no prior value exists, use the admission creatinine as baseline. 2

Staging System

Stage 1 (Mild)

  • SCr increase 1.5-1.9 times baseline OR
  • SCr increase ≥0.3 mg/dL (26.5 μmol/L) OR
  • Urine output <0.5 mL/kg/h for 6-12 hours 1

Stage 2 (Moderate)

  • SCr increase 2.0-2.9 times baseline OR
  • Urine output <0.5 mL/kg/h for ≥12 hours 1

Stage 3 (Severe)

  • SCr increase ≥3.0 times baseline OR
  • SCr increase to ≥4.0 mg/dL (353.6 μmol/L) with acute increase ≥0.3 mg/dL OR
  • Initiation of renal replacement therapy OR
  • In patients <18 years: eGFR decrease to <35 mL/min/1.73 m² OR
  • Urine output <0.3 mL/kg/h for ≥24 hours OR
  • Anuria for ≥12 hours 1

Stage-Specific Management

Stage 1 Management

For Stage 1A (SCr <1.5 mg/dL):

  • Close monitoring with serial creatinine measurements
  • Remove nephrotoxic drugs (NSAIDs, aminoglycosides, ACE inhibitors/ARBs if hypotensive)
  • Withdraw or taper diuretics and beta-blockers
  • Expand plasma volume with isotonic crystalloids
  • Treat infections promptly when identified 2

For Stage 1B (SCr ≥1.5 mg/dL):

  • All Stage 1A measures plus
  • Withdraw diuretics (if not already done)
  • Volume expansion with albumin 1 g/kg for 2 days
  • More aggressive monitoring as these patients have higher mortality and progression risk 3

Stage 2 Management

  • Continue all Stage 1B interventions
  • Assess for hepatorenal syndrome criteria if cirrhotic
  • Consider nephrology consultation
  • Monitor for progression to Stage 3
  • Evaluate need for ICU-level care 2

Stage 3 Management

  • Immediate nephrology consultation required
  • Assess for renal replacement therapy indications:
    • Refractory hyperkalemia
    • Volume overload unresponsive to diuretics
    • Metabolic acidosis (pH <7.1)
    • Uremic complications (encephalopathy, pericarditis, bleeding)
    • Certain toxin removal 4, 5
  • If hepatorenal syndrome criteria met: vasoconstrictors (terlipressin, norepinephrine, or midodrine/octreotide) plus albumin 2
  • Optimize hemodynamics and avoid further nephrotoxic insults

Critical Management Principles Across All Stages

Fluid Management:

  • Early rapid restoration of circulatory volume in first 24-48 hours
  • After initial resuscitation, limit fluids to avoid volume overload
  • Use balanced crystalloids or isotonic saline (evidence remains mixed) 6

Medication Review:

  • Discontinue all nephrotoxic medications immediately
  • Adjust all drug dosing for reduced GFR
  • Avoid iodinated contrast unless absolutely necessary 7

Monitoring:

  • Daily creatinine and electrolytes
  • Strict intake/output monitoring
  • Daily weights
  • Assess volume status clinically 4

Common Pitfalls

The Stage 3 creatinine criterion of ≥4.0 mg/dL requires an acute rise of ≥0.3 mg/dL - this prevents misclassifying stable CKD patients as having severe AKI. However, this has not been validated in CKD populations and small fluctuations may represent normal variation. 1

Urine output criteria are often unreliable in cirrhotic patients due to baseline oliguria with sodium retention, diuretic effects, and inaccurate ward-based collection. Use creatinine criteria primarily in this population unless bladder catheter is in place. 2

Stage 1 AKI is heterogeneous - a 0.3 mg/dL rise may represent vastly different percentage increases depending on baseline creatinine, which is why substaging (1A vs 1B) improves prognostication in cirrhosis. 3

Follow-Up

Evaluate all patients 3 months post-AKI for resolution, new-onset CKD, or worsening of pre-existing CKD. Even patients with complete AKI resolution remain at increased risk for future CKD and require ongoing monitoring. 1

References

4
Research

Acute Kidney Injury: Diagnosis and Management.

American family physician, 2019

5
Research

Acute kidney injury: a guide to diagnosis and management.

American family physician, 2012

6
Research

Management of patients at risk of acute kidney injury.

Lancet (London, England), 2017

Related Questions

What is the appropriate management of acute kidney injury secondary to blood loss in an adult patient?
What is the appropriate evaluation and initial management for acute kidney injury?
What is the recommended initial management for a patient with intrarenal (intrinsic) acute kidney injury?
What are the definition, diagnosis, clinical presentation, and treatment of acute kidney injury?
Which diagnostic examinations should be ordered for a patient with KDIGO stage 3 acute kidney injury?
What is the protocol for administering low‑dose dexamethasone (Doyle‑Davis regimen) to preterm infants (<28 weeks gestation, <1 kg) with moderate to severe bronchopulmonary dysplasia who remain ventilator‑dependent after the first week of life?
Is co‑administration of flavoxate with nitrofurantoin safe?
What is the oral bioavailability of clindamycin tablets compared with intravenous clindamycin, and can the oral dose replace the IV dose?
What is the definition of emergency department patient acuity level 2?
What is the recommended erythromycin dose and regimen for adult patients with paralytic ileus?
What is the appropriate management for a 35-year-old male presenting with chest tightness but no chest pain?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.